Cargando…

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)

BACKGROUND: Two large-scale phase 3 clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]) demonstrated that, in adults ≥ 50 years of age followed over a mean period of 3.1 and 3.7 years respectively, the adjuvanted recombinant zoster vaccine (RZV) was efficacious against herpes zoster (HZ)...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutry, Céline, Hastie, Andrew, Shi, Meng, Diez-Domingo, Javier, Tinoco, Juan Carlos, Yu, Chong-Jen, Pirrotta, Paola, Kalema, George, Schuind, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776067/
http://dx.doi.org/10.1093/ofid/ofaa417.007